



Spectros Corporation Signs Distribution Agreements in Korea, Switzerland, Denmark

PORTOLA VALLEY, Calif., August 31, 2011/PRNewswire/ -- Spectros, developer and manufacturer of the T-Stat VLS Tissue Oximeter announces its success in the reconstructive plastic surgery market.

Spectros Corporation announced today an expansion of its distribution channels in Europe and Asia with the signing of 3 new distributors based in Korea, Switzerland, and Denmark. These groups join other distributors already selling Spectros products outside of the U.S.

"We are excited that distributors are increasingly recognizing the opportunity offered by the T-STAT 303 VLS Tissue Oximeter " noted Director of Sales Elizabeth van Thillo-Rohlff. "This move continues our aggressive expansion into new and emerging markets."

Spectros T-Stat and Continuum Oximeters are currently the only broadband tissue oximeters on the market in the U.S. and Europe. T-Stat and Continuum compete in the marketplace with INVOS® oximeters marketed by Covidien, and FORE-SIGHT® oximeters marketed by CAS Medical. In reconstructive surgery, T-Stat competes with oximeters marketed by ViOptix and O2C. An expanded array of probes, including broadband NIRS Continuum® cerebral probes are currently in testing, pending FDA approval and release anticipated over the next year.

About Spectros

Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's champion product, the T-Stat Tissue Oximeter, is the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue. T-Stat is the only commercially-available tissue oximeter that utilizes state-of-the-art broadband visible light spectroscopy (VLS) and broadband near-infrared (NIRS) technology. The non-invasive T-Stat system is used clinically to provide a continuous and real-time absolute value, utilizing 260 wavelengths, over the competing oximeter product lines that only use 2-4.

Spectros also develops molecular diagnostic tools for breast and prostate cancer, currently in phase I/II clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.

(Note: Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns. Certain Spectros applications described above have not been reviewed and approved by the FDA, and are therefore labeled "for investigational use only." T-Stat and Continuum are trademarks of the Spectros Corporation. INVOS is a trademark of Somanetics and Covidien. FORE-SIGHT is a trademark of CAS Medical).

For further information, visit www.spectros.com.

SOURCE Spectros

Media Contact: Ms. Elizabeth van Thillo-Rohlff of Spectros, +1-650-529-2865, info@spectros.com